OverviewSuggest Edit

Immucor is dedicated to offering products that enable patients anywhere who are in need of blood or an organ to receive the right match that is safe, accessible and affordable. The result is life changing for a patient in need of a transfusion or transplant. Immucor is a leading provider of transfusion and transplantation diagnostic products worldwide. Our new corporate identity illustrates the right match of donors with patients in need of blood or an organ as well as Immucor’s partnership with healthcare organizations in need of innovation and productivity.
TypePrivate
Founded1982
HQNorcross, US
Websiteimmucor.com
Employee Ratings2.7

Latest Updates

Employees (est.) (Sept 2020)878
Revenue (FY, 2016)$380 M(-2%)
Cybersecurity ratingCMore

Key People/Management at Immucor

Avi Pelossof

Avi Pelossof

President and Chief Executive Officer
Dominique Petitgenet

Dominique Petitgenet

Chief Operating Officer and Chief Financial Officer
Show more

Immucor Office Locations

Immucor has offices in Norcross and Dartmouth
Norcross, US (HQ)
3130 Gateway Dr
Dartmouth, CA
5 Isnor Dr
Show all (2)

Immucor Financials and Metrics

Summary Metrics

Founding Date

1982

Immucor investors

Show all financial metrics

Immucor Revenue

Immucor's revenue was reported to be $379.97 m in FY, 2016
USD

Revenue (Q3, 2017)

94.0m

Gross profit (Q3, 2017)

58.6m

Gross profit margin (Q3, 2017), %

62.4%

Net income (Q3, 2017)

(7.7m)

EBIT (Q3, 2017)

8.1m

Cash (28-Feb-2017)

10.0m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

333.1m336.7m347.8m388.1m389.3m380.0m

Cost of goods sold

139.6m143.7m144.0m

Gross profit

248.4m245.6m236.0m

Gross profit Margin, %

64%63%62%
Quarterly
USDQ1, 2011Q2, 2011Q3, 2011Q2, 2012Q3, 2012Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

83.6m81.5m83.3m83.0m81.4m86.2m96.0m100.2m91.0m102.4m96.3m95.6m96.7m96.2m88.9m98.6m93.7m94.0m

Cost of goods sold

32.4m36.8m35.8m34.0m34.6m37.9m34.1m36.5m38.2m35.3m

Gross profit

58.6m65.6m60.5m61.6m62.1m58.4m54.8m62.1m55.5m58.6m

Gross profit Margin, %

64%64%63%64%64%61%62%63%59%62%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

302.6m18.6m29.4m23.6m18.4m10.3m

Accounts Receivable

63.3m66.4m68.1m69.6m67.7m62.0m

Prepaid Expenses

11.2m11.7m11.6m12.6m11.2m

Inventories

32.9m33.4m45.9m49.2m41.8m46.9m
Annual
USDFY, 2011FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

89.3m(39.1m)(182.3m)(60.7m)(43.8m)

Depreciation and Amortization

18.2m71.7m71.3m71.3m69.5m

Inventories

8.2m(9.8m)(15.6m)(3.1m)(12.0m)

Accounts Payable

2.4m(305.0k)1.7m(1.4m)8.3m
USDQ1, 2011

Financial Leverage

1.1 x
Show all financial metrics

Immucor Cybersecurity Score

Cybersecurity ratingPremium dataset

C

79/100

SecurityScorecard logo

Immucor Online and Social Media Presence

Embed Graph

Immucor News and Updates

Liquid Biopsy Market Growth Rate of 23.80% by 2026 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by QIAGEN, MDxHealth, CareDx, Inc., Immucor, Inc., Menarini Silicon Biosystems, Guardant Health, Myriad Genetics

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Data Bridge Market Research has added a new report titled Global Liquid Biopsy Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Global Liqu…

Transplant Diagnostics Market Strategic Healthcare Industry Influence Data | Future Recommendations and Forecasts by 2023

Global Transplant Diagnostics Market Research Report, By Products (Instrument, Reagent, Software And Services), By Technology (Non-Molecular Assay, Molecular Assay), By Application (Heart, Lungs, Liver, Kidney And Other), By Method Type (Pre-Transplant Screening And Post-Transplant Screening), By En…

Future Growth of Transplant Diagnostics Market is expected to grow at a CAGR of 7.2% during forecasted period 2017-2023

Market Research Future published a Half Cooked research report on “Global Transplant Diagnostics Market Research Report - Forecast to 2023– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday

Immucor Frequently Asked Questions

  • When was Immucor founded?

    Immucor was founded in 1982.

  • Who are Immucor key executives?

    Immucor's key executives are Avi Pelossof and Dominique Petitgenet.

  • How many employees does Immucor have?

    Immucor has 878 employees.

  • What is Immucor revenue?

    Latest Immucor annual revenue is $380 m.

  • What is Immucor revenue per employee?

    Latest Immucor revenue per employee is $432.8 k.

  • Who are Immucor competitors?

    Competitors of Immucor include Bio-Rad, Omega Diagnostics and Oxford Immunotec.

  • Where is Immucor headquarters?

    Immucor headquarters is located at 3130 Gateway Dr, Norcross.

  • Where are Immucor offices?

    Immucor has offices in Norcross and Dartmouth.

  • How many offices does Immucor have?

    Immucor has 2 offices.